Intellia Therapeutics (NTLA) Return on Sales (2016 - 2025)
Historic Return on Sales for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to 7.6%.
- Intellia Therapeutics' Return on Sales rose 69600.0% to 7.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.74%, marking a year-over-year increase of 35900.0%. This contributed to the annual value of 8.4% for FY2024, which is 44300.0% up from last year.
- As of Q3 2025, Intellia Therapeutics' Return on Sales stood at 7.6%, which was up 69600.0% from 7.2% recorded in Q2 2025.
- Over the past 5 years, Intellia Therapeutics' Return on Sales peaked at 66.48% during Q4 2023, and registered a low of 238.81% during Q3 2021.
- For the 5-year period, Intellia Therapeutics' Return on Sales averaged around 17.14%, with its median value being 7.81% (2022).
- As far as peak fluctuations go, Intellia Therapeutics' Return on Sales tumbled by -2375600bps in 2021, and later surged by 2310100bps in 2022.
- Intellia Therapeutics' Return on Sales (Quarter) stood at 6.22% in 2021, then fell by -24bps to 7.72% in 2022, then surged by 961bps to 66.48% in 2023, then crashed by -115bps to 9.77% in 2024, then rose by 22bps to 7.6% in 2025.
- Its Return on Sales was 7.6% in Q3 2025, compared to 7.2% in Q2 2025 and 6.75% in Q1 2025.